CJC-1295 and Ipamorelin: FDA Status

When a patient asks about CJC-1295 and ipamorelin, start with the approval record. Then separate that answer from questions about compounding. This page brings those records together so your practice can identify what is documented and what still needs review.

Keep the source and review date beside any regulatory statement your team shares. A useful internal review should distinguish an application search, a nomination record and the requirements your attorney needs to assess. Treat each as a separate question before drawing a conclusion for your practice.

Are CJC-1295 and ipamorelin FDA approved?

No. A Drugs@FDA search on November 4, 2026 returned no application listing either CJC-1295 or ipamorelin as an active ingredient.

The supplied searches checked active ingredient names beginning with "cjc" and "ipamorelin." Both returned no matches. That is the basis for the approval answer on this page: neither appeared as an active ingredient in an FDA application in those searches.

Keep that finding precise when answering a patient or preparing an internal note. Record the ingredient name, the database searched and the date checked. The finding answers the approval question. This page addresses the separate compounding records below, without treating the application search as a complete assessment of a particular compounded product.

What has FDA said about CJC-1295?

FDA lists CJC-1295 among substances previously in 503A category 2 whose nominations were withdrawn, and it identifies safety concerns.

Those concerns include possible immunogenicity and impurity issues. FDA also identifies serious adverse events and says available clinical data are limited. These are statements from FDA's safety record, separate from the nomination's administrative history.

The reason given for leaving category 2 is withdrawal by the nominator. When reviewing this entry, preserve that reason in your notes. Describing the change simply as removal from a category leaves out the detail that explains the change.

For your practice's review, capture both parts of the record: the withdrawn nomination and FDA's stated concerns. Ask your attorney to assess the record as a whole before reaching a conclusion about a specific compounded product.

What has FDA said about ipamorelin?

FDA lists ipamorelin acetate in 503B category 2, where it has been listed since September 29, 2023, and among withdrawn 503A nominations.

FDA identifies possible immunogenicity, concerns about aggregation or peptide-related impurities, and unnatural amino acids that complicate characterization. FDA's record describes a published study that reported serious adverse events, including death. The withdrawn 503A nomination and the 503B category 2 entry are distinct records. Do not collapse them into a single statement that the substance has left category 2.

Category 2 means FDA has identified significant safety risks pending further evaluation. FDA says it would consider enforcement action against compounding with substances in that category. For an internal review, retain the section number alongside the category so the statement remains specific to the record being discussed.

Under FDA's compounding questions and answers (opens in a new tab), 503B outsourcing facilities are a category of compounders established in 2013 by the Drug Quality and Security Act. They are subject to increased quality standards. For context on the two frameworks, see 503A and 503B compounding differences.

How do the FDA records compare?

Both peptides have withdrawn 503A nominations and no matching Drugs@FDA application, while the supplied record also establishes ipamorelin acetate's 503B category 2 listing.

HHS announced the availability of a draft enforcement discretion policy in its October 30, 2026 Federal Register notice (opens in a new tab).

Neither appears in Appendix A of the HHS draft peptide policy (opens in a new tab). Its six listed peptides are BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.

The CJC-1295 503B cell marks a limit of the evidence supplied for this page. It should remain an open verification item in your review. Do not turn an unestablished record into an affirmative statement about eligibility.

Does leaving category 2 make a peptide legal to compound?

No. Withdrawal of a nomination does not, by itself, establish that a peptide may legally be compounded.

Under section 503A, the bulk substance must meet the applicable requirements through one of these bases:

• If an applicable United States Pharmacopeia or National Formulary monograph exists, comply with it and the applicable USP compounding chapter.
• If no applicable monograph exists, be a component of an FDA-approved drug product.
• If neither of those bases applies, appear on FDA's 503A bulks list.

FDA also says it does not intend to place substances nominated on or after January 7, 2025 into these categories. A category search therefore needs to be read alongside the underlying requirements. Neither CJC-1295 nor ipamorelin is among the six peptides in the HHS draft policy's Appendix A.

Whether a specific compounded product meets section 503A or 503B is a fact-specific legal question this page does not answer. Ask your own attorney to identify the applicable framework and evaluate the particular product. Keep that assessment separate from a summary of a withdrawn nomination.

What should a practice check?

Your practice should check labeling, approval statements, evidence for claims and applicable oversight with its state boards and its own attorney.

Begin with the following review questions:

• What does the labeling establish? In a June 17, 2026 warning letter (opens in a new tab), FDA said research-use-only and not-for-human-consumption statements did not prevent it from finding that the products were drugs intended for human use. Do not treat those phrases alone as an answer to your regulatory questions.
• Is the approval description accurate? FDA says compounded drugs are not FDA-approved. FDA does not verify their safety, effectiveness or quality before marketing. Ask your team to keep that distinction explicit in any draft communication about compounding.
• What evidence supports a claim? The FTC's Health Products Compliance Guidance (opens in a new tab) says health benefit or safety claims for health-related products require competent and reliable scientific evidence. Have proposed claims reviewed against that standard before sharing them.
• Which oversight applies? State boards of pharmacy generally oversee state-licensed pharmacies day to day. FDA primarily oversees and inspects 503B outsourcing facilities, which must follow current good manufacturing practice requirements. Confirm the relevant oversight with your state boards and ask your attorney to assess your practice's specific questions.

Related reading

• Are Peptides Legal? FDA Status and Compounding Rules
• Telehealth Regulation News: How to Ensure Virtual Compliance
• How to Pick the Right Medical Spa Lawyer for Your Clinic
• Med Spa Laws by State: Ownership and Licensing

Sources

• FDA: Bulk Substances With Significant Safety Risks (opens in a new tab), checked November 6, 2026.
• FDA: Bulk Substances Under Section 503A (opens in a new tab), checked November 6, 2026.
• FDA: Compounding Questions and Answers (opens in a new tab), checked November 6, 2026.
• HHS: Draft 503A Compounding Policy Availability Notice (opens in a new tab), checked November 6, 2026.
• HHS: Draft 503A Peptide Enforcement Policy, Appendix A (opens in a new tab), checked November 6, 2026.
• FDA: Warning Letter, June 17, 2026 (opens in a new tab), checked November 6, 2026.
• FTC: Health Products Compliance Guidance (opens in a new tab), checked November 6, 2026.